Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sesen Bio, Inc. - Common Stock (NQ:SESN)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Mar 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Sesen Bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Sesen Bio Stockholders Approve Merger with Carisma Therapeutics
From Sesen Bio, Inc.
Via Business Wire
Sesen Bio Reports Fourth Quarter and Full-Year 2022 Financial Results
From Sesen Bio, Inc.
Via Business Wire
Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote “FOR” All Proposals to Approve Pending Merger With Carisma
From Sesen Bio, Inc.
Via Business Wire
Leading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special Meeting
From Sesen Bio, Inc.
Via Business Wire
Sesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending Merger
From Sesen Bio, Inc.
Via Business Wire
BML, One of Sesen Bio’s Top Stockholders, Announces Support for Pending Merger with Carisma Therapeutics
From Sesen Bio, Inc.
Via Business Wire
Sesen Bio and Carisma Therapeutics Announce Increased Special Cash Dividend and Stockholder Support for Pending Merger
From Sesen Bio, Inc.
Via Business Wire
Sesen Bio Files Investor Presentation in Connection with Pending Carisma Therapeutics Merger
From Sesen Bio, Inc.
Via Business Wire
Sesen Bio Receives NASDAQ Delisting Notice
From Sesen Bio, Inc.
Via Business Wire
Sesen Bio Reiterates Confidence that Pending Merger with Carisma is in Best Interests of Stockholders
From Sesen Bio, Inc.
Via Business Wire
Investor Group Issues Letter to the Boards of Sesen Bio and Carisma Rejecting Their Apparent Attempt to Purchase Merger Support
From On behalf of Bradley L. Radoff
Via Business Wire
Sesen Bio Files Definitive Proxy Statement and Mails Letter to Stockholders in Connection with Pending Merger with Carisma Therapeutics
From Sesen Bio, Inc.
Via Business Wire
Investor Group Issues Letter to Sesen Bio’s Board of Directors Regarding Intent to Vote AGAINST Proposed Carisma Merger
From On behalf of Bradley L. Radoff
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Sesen Bio, Inc. (Nasdaq - SESN), IsoPlexis (Nasdaq - ISO), Trean Insurance Group, Inc. (Nasdaq - TIG), Brunswick Bancorp (OTC – BRBW)
From Brodsky & Smith LLC
Via GlobeNewswire
Sesen Bio Reiterates Confidence in Pending Merger with Carisma Therapeutics
From Sesen Bio, Inc.
Via Business Wire
Investor Group Reiterates Intent to Vote AGAINST Sesen Bio’s Value-Destructive Merger with Carisma
From On behalf of Bradley L. Radoff
Via Business Wire
Sesen Bio and Carisma Therapeutics Announce Substantial Increase to Expected Special Cash Dividend in Connection with Pending Merger
From Sesen Bio, Inc.
Via Business Wire
Sesen Bio Reports Third Quarter 2022 Financial Results and Business Update
From Sesen Bio
Via Business Wire
SESEN BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Sesen Bio, Inc. - SESN
From Kahn Swick & Foti, LLC
Via Business Wire
SESN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Sesen Bio, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Sesen Bio and Carisma Therapeutics Announce Merger Agreement
From Sesen Bio, Inc.
Via Business Wire
Sesen Bio Reports Second Quarter 2022 Financial Results and Business Update
From Sesen Bio
Via Business Wire
Sesen Bio Announces Strategic Decision to Pause Clinical Development of Vicineum™ in the US
From Sesen Bio
Via Business Wire
Sesen Bio Reports First Quarter 2022 Financial Results and Business Update
From Sesen Bio
Via Business Wire
Sesen Bio Provides Strategic Update
From Sesen Bio
Via Business Wire
Sesen Bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Anticipated Regulatory Path Forward for the Company’s Lead Product Candidate, Vicineum™
From Sesen Bio
Via Business Wire
Sesen Bio Further Enhances Team with Key Hires
From Sesen Bio
Via Business Wire
Sesen Bio Announces Anticipated Regulatory Path Forward for Vicineum™
From Sesen Bio, Inc.
Via Business Wire
Sesen Bio Strengthens Medical Team
From Sesen Bio
Via Business Wire
Sesen Bio Director Jane Pritchett Henderson Transitions to CEO Advisor Role
From Sesen Bio
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.